Botulinum Toxins, Therapeutic
Abstract
Of the therapeutically used botulinum toxins, only onabotulinumtoxinA has been studied during breastfeeding and only in cosmetic doses. It was not detectable in the milk of two women and detectable in only minute amounts in 5 others after 40 to 92 units injected into the face. A systematic review found that among 94 cases of reported breastfeeding, no adverse infant events or developmental delays were observed at 1 year.[1] International guidelines considers onabotulinumtoxinA acceptable in breastfeeding women with chronic migraine, and it is often used in nursing mothers by dermatologists, including dermatologists themselves.[2-4] High doses for other conditions have not been studied.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.